Giannini A J, Nakoneczie A M, Melemis S M, Ventresco J, Condon M
Chemical Abuse Centers Inc., 721 Boardman-Poland Road, Suite 200, Boardman, OH 44512-5105, USA.
Psychiatry Res. 2000 Feb 14;93(1):83-7. doi: 10.1016/s0165-1781(99)00116-x.
The authors compared the antimanic effects of a verapamil-magnesium oxide (V-M) combination with a verapamil-placebo combination (V-P) in patients pretreated with verapamil. BPRS scores and serum magnesium levels were compared. The V-M combination was found to be significantly more effective than V-P in reducing manic symptoms (P=0.015). Serum magnesium levels were significantly higher in the V-M group (P<0.04). These data suggest that magnesium may increase antimanic efficacy of verapamil by mechanisms which may operate at the intracellular level. The magnesium-verapamil combination may have clinical application as an adjunct to verapamil in the maintenance therapy of mania.
作者比较了维拉帕米 - 氧化镁(V - M)组合与维拉帕米 - 安慰剂组合(V - P)对已接受维拉帕米预处理患者的抗躁狂作用。比较了简明精神病评定量表(BPRS)评分和血清镁水平。发现V - M组合在减轻躁狂症状方面比V - P组合显著更有效(P = 0.015)。V - M组的血清镁水平显著更高(P < 0.04)。这些数据表明,镁可能通过可能在细胞内水平起作用的机制增加维拉帕米的抗躁狂疗效。镁 - 维拉帕米组合可能作为维拉帕米在躁狂症维持治疗中的辅助药物具有临床应用价值。